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Immunizat ion  of Balb/c mice with a homogeneously purif ied recombinant  
human La/SS-B protein resulted in act ivation of an autoreactive B cell 
secreting a novel monoclonal  ant i -La ant ibody termed La4B6. La4B6 
reacted with La protein f rom a variety of sources inc luding human,  bovine, 
rat  and mouse. ATP  blocked the b ind ing of La4B6 to recombinant  La 
protein.  The human epitope was identif ied as consist ing of the amino acid 
sequence SKGRRFKGKGKGN,  which includes the proposed ATP-b ind ing  
site of the La protein.  In the human and bovine La protein,  the epitope 
exists as a cont inuous amino acid sequence. In rat  and mouse the epitope 
was found to consist of the :amino acid sequence SKG interrupted by a 
species-specific insert  of 16 amino acids, and followed by the second hal f  of 
the epitope, the amino acid sequence RRFKGKGKGN.  Our  data suggest 
that in the case of the rat  and mouse La proteins the two separated parts of 
the epitope are able to form a conformat ional  epitope which looks s imi lar  
to the cont inuous human epitope. © 1995 Academic Press Limited 
Abbreviat ions:  aa, amino acid; cLSM, confocal Laser Scanning Microscopy; 
ECL, enhanced chemoluminescence; IPTG, isopropyl [3-D-thiogalactopyranoside; 
NBT, 4-nitro-blue-tetrazolium chloride; BCIP, 5-bromo-4-chloro-3-indolyl phos- 
phate; nt, nucleotide; PVDF, p01yvinylidene fluoride; pSS, primary Sj6gren's 
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syndrome; scRNP, small cytoplasmic ribonucleoprotein; snRNP, small nuclear 
ribonucleoprotein; SS-B, Sjrgren's yndrome associated antigen B (i.e. La). 
I n t roduct ion  
Sera of patients with systemic immuno-inflammatory autoimmune diseases uch as 
Systemic Lupus Erythematosus or primary Sjrgren's syndrome frequently contain 
autoantibodies to nuclear antigens. One of the targets of these autoantibodies is the 
La/SS-B antigen, a protein with a molecular weight of about 47-kD [1, 2]. In the 
nucleus the La protein may function as a transcription termination factor of RNA 
polymerase III [3, 4]. This function is in accord with association of the La protein 
with nearly all RNA polymerase III transcripts including precursors of 5S RNA, 
tRNA and 7S RNA, the Y RNAs and some viral RNAs [5]. In agreement with its 
function as a transcription termination factor the La protein was characterized asan 
enzyme being able to melt DNA/RNA hybrids and presumably dsRNA [6]. In 
recent studies Meerovitch et al. characterized a cellular cytoplasmic protein, 
involved in internal initiation of translation of poliovirus mRNAs, as the La protein 
[7]. Subsequently it was shown that La is indeed an ATP-dependent dsRNA- 
unwinding enzyme [8]. In agreement with such unwinding activity, Topfer and 
coworkers identified a putative ATP-binding motif [9] which is known to be 
conserved in dsRNA unwinding enzymes [10]. In a recent report Semsei et al. [11] 
described this proposed ATP-binding site as having been conserved during 
evolution but containing a species-specific insert in the rat and mouse La protein. 
The species-specific nsert was characterized to be a partial repeat of flanking 
sequences [11]. According to the mimicry hypothesis, such a region could be a 
possible target for experimentaily inducible autoimmunization. 
In this report we describe the induction of a novel monoclonal routine anti-La 
autoantibody, which was elicited by immunization of mice with a recombinant. 
human La protein. Epitope mapping studies support the idea that the species- 
specific insert might be involved in the experimentally induced autoimmune 
reaction. 
Mater ia l s  and methods  
Anti-human antibodies conjugated with Fluorescein (FITC) and anti-mouse anti- 
bodies conjugated with Cy3 were purchased from Medac (Hamburg, Germany). 
Blocking reagent was obtained from Boehringer Mannheim (Mannheim, 
Germany). Anti-mouse IgG conjugated with peroxidase developed in sheep 
((Fab') 2 fragments) adsorbed with human serum proteins (A-7282; 20 U/ml), 
anti-human IgG (7-chain specific) conjugated with alkaline phosphatase (A3150; 
8 U/mol), anti-mouse IgG developed in sheep ((Fab') 2 fragments) adsorbed with 
human serum proteins (A-0532) and isopropyl [3-D-thiogalactopyranoside (IPTG) 
were obtained from Sigma (St Louis, MA, USA). The enhanced chemolumines- 
cence (ECL) Western blotting detection reagents were from Amersham-Buchler 
(Braunschweig, Germany). 4-Nitro-blue-tetrazolium chloride (NBT) and 5- 
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bromo-4-chloro-3-indolyl phosphate (BCIP) from Roth (Karlsruhe, Germany). 
Synthetic peptides were purchased from the protein routine laboratory of the 
Johannes-Gutenberg University of Mainz, Dep. of Physiol. Chem. and Pathobio- 
chem. (Mainz, Germany). PVDF-membrane (IPVH 000 10; pore size 0.45 pm) 
was obtained from Millipore (Bedford, MA, USA), and nitrocellulose filters 
(BA83/21) from Schleicher and Schfill (Dassel, Germany). 
Monoclonal antibodies and sera 
Immunization, development and subcloning of the hybridomas as well as ELISA 
were performed as described previously [12]. The immunization was performed in 
three steps. In each step 50 ~tg of the gel purified recombinant human La protein 
was injected intraperitoneally into Balb/c AnHan mice. 
Monospecific patient anti-La antibody 
Human monospecific anti-La antibody was prepared by adsorption of a mono- 
specific anti-La serum (Ma;6) to the recombinant human La protein covalently 
linked to Sepharose-4B. Elution of the bound anti-La antibody was performed as 
described [13]. 
Peptide ELISA 
ELISA plates were prepared by coating 200 ~tl of peptide solution containing 2 ~tg 
of the respective peptide dissolved in Tris/HC1 (pH 7.4, containing 150 mM NaC1, 
0.1% Tween20 (TBST)). The plates were coated overnight at 4°C, blocked with 
blocking reagent (4%) for 4 h at 4"C, and washed,with TBST (3 x 5 min). Then 
cell culture supernatant of the hybridoma secreting the anti-La mAb rLa4B6 was 
added, incubated for 30 min and the wells were washed with TBST. Incubation 
with the secondary anti-mouse antibody conjugated with peroxidase was performed 
in TBST containing 0.5% blocking reagent for 30 min. After washing with 
TBST (3 × 5 rain) the formed immune complexes were detected using 
o-Phenylenediamine as substrate. A maximum O.D. of 0.68 was measured for 
peptide 1 (see Figure 5) and set to 100%. 
Cell culture and staining procedures 
The following cell lines were used: Human XPTA cells (13-15), bovine MDBK 
cells (ATCC CCL 22), rat PC12 cells (ATCC CRL 1721) and mouse 3T3 cells 
(ATCC CCL 92). 
Cells were grown to confluency on coverslips in RPMI 1640 or DMEM medium 
containing 10% FCS and fixed with methanol containing 0.02% EGTA at - 20°C 
for 1 h. Indirect immunofluorescence of cells with the anti-La mAb was performed 
by incubating the fixed cells, which had been rehydrated for 5 min with PBS, with 
cell culture supematant for at least 15 rain. The cells were washed with PBS (5 
min) and the bound anti-La mAb was detected using Cy3-conjugated goat 
anti-mouse antibody. The staining of rat and mouse cells proved to be critical. Best 
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results were obtained when the staining procedure was performed on ice using 
protein A purified anti-La mAb dialyzed against PBS. Indirect immunofiuorescence 
labelling using immunoadsorbed patient anti-La antibody was performed using the 
same procedure. The bound human anti-La antibody was detected with species- 
specific anti-human antibody conjugated with FITC. Four double immunofluores- 
cence, the cells which had already been stained with the anti-La mAb La4B6, as 
described above, were subsequently incubated with the patient anti-La antibody. In 
all cases the incubation time for the secondary antibody was 15 min. The staining 
occurred at room temperature and the unbound secondary antibodies were 
removed by washing with PBS (twice, 5 min). The stained cells were mounted 
using PBS/glycerol (1:1 [v/v]). 
Epifluorescence microscopy 
Stained cells were analysed with a Zeiss Axiophot microscope equipped with 
epifluorescence optics and filter systems specific for the fluorescence dyes used 
[12-15]. 
Confocal aser scanning microscopy 
Confocal aser scanning microscopy (cLSM) was performed using a Zeiss LSM 10. 
Cells were cut automatically into horizontal sections (512 x 512 pixels/8 bit, 
objective lenses Plan-Neofluar 40 x/1.3 oil). Evaluation of the stored stacks of the 
horizontal optical sections was performed with the LSM 10 image processing unit. 
Preparation of cell extracts 
Monolayer cells, grown to confluency, were lysed in hot SDS-PAGE sample 
solution (0.1 M Na2HPO 4, pH 8.3; 20% [w/v] sucrose, 1% SDS, 1 mM PMSF; 
500 ~tl per 200 ml fask). The protein extract was heated in an Eppendorf tube for 
5 min at 95°C, centrifuged for 15 min at 11 000 × g and frozen until use. 
SDS polyacrylamide g l electrophoresis and immunoblotting 
SDS-PAGE was performed according to Laemmli [16] and immunoblotting to 
PVDF-membrane according to Matsudaira [17]. Prior to electrophoresis the 
samples were heated for 3 rain to 95°C in the presence of 1 mM [3-mercaptoethanol 
if not stated otherwise. Immune complexes on the blots were visualized using either 
the ECL-Westem blotting detection system or the alkaline phosphatase system 
using NBT-X-phosphate or BCIP/NBT as substrates. 
Isolation of La cDNAs and preparation of deletion mutants 
A human cDNA library was prepared from peripheral blood lymphocytes of a 
patient with pSS [11] and screened using patient anti-La serum Ma [6]. The two 
longest clones (termed La19 and La23) were sequenced (EMBL Acc. No.: 
X69804). In both clones the complete xonl of the known La mRNA sequence was 
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replaced by an alternative 5'-terminus. This difference is not relevant for the 
present study as the identified epitope (see Results) is located in the C-terminus of 
the La protein. Deletion mutants were made from La19 and La23, in both cases 
using the same restriction site. However, as the La insert in La l9  is inverted, 
expression of deletion mutants obtained from this clone (La19) resulted in La 
proteins shortened from the C-terminus, while expression of the deletion mutants 
obtained from the clone La23 resulted in La proteins with N-terminal truncations. 
Due to the inversion of the La insert in clone La19, the expression of the 
C-terminally truncated La proteins did not depend on (1) the fl-Gal derived ATG 
and (2) the reading frame. Similarly, all the deletion mutants derived from La23 
expressed immunoreactive La protein independent on the reading frame of the 
fl-Gal derived ATG until the internal ATG (encoding aa M (223)) was deleted. 
Deletion mutants lacking the aa M (223) expressed immunoreactive La protein 
only when the fl-Gal derived ATG was in the reading frame of the La protein, which 
indicates that an internal initiation may occur at this ATG in E. coli. Deletion 
mutants (for example, clones 23 to 25; Figure 3A) not containing the La insert in 
the reading frame of the fl-Gal derived ATG were not or less efficiently expressed 
and therefore not useful. 
DNA for preparation of the deletion mutants was prepared from small scale 
cultures (up to 12 ml) using the protocol of Holmes and Quigley [18] modified 
according to Sambrook et al. [19]. To create deletion clones the method originally 
described by Henikoff [20] was used. The DNA to be deleted was doubly digested 
with either Sac I (La23) or BstX I (Lal9) and EcoRI from which site deletions 
started. EcoRI represents the 5'-cloning site and served as the initiation site of 
deletion. DNA of each deletion mutant was prepared and sequenced as described 
[11]. 
Expression of recombinant La protein 
The human recombinant La protein was expressed in E. coli strain 
BL21(DE3)pLysS as described by Slobbe et al. [21]. The La protein was subse- 
quently purified from the bacterial lysate by ion exchange chromatography using 
DEAE cellulose (Whatman DE52) and phosphocellulose (Whatman P11) resins. 
DEAE cellulose column chromatography was performed with a buffer containing 
25 mM TrisFHC1, pH 8.0, 100 mM NaC1, 1 mM EDTA, 1 mM dithioerythritol. 
The flow through of the DEAE column, containing the La protein, was applied to 
the phosphocellulose column, which was equilibrated with 50 mM HEPES-KOH,  
pH 7.9, 100 mM NaC1, 1 mM dithioerythritol. Bound material was eluted with a 
linear salt gradient and the La protein eluted at approximately 700 mM NaC1. 
Alternatively, expression of La inserts in pBluescript II SK( - )  were performed 
after transformation i to the bacterial strain BL21(DE3)pLysS using the Studier 
system [22] modified according to a protein expression protocol of Stratagene 
(Heidelberg, Germany). After expression the bacterial suspensions were centri- 
fuged for 15 min at 1600 x g (4°C) and the pelleted bacteria were resuspended in
lysis buffer (50 mM Tris/HC1, pH 8.0; 10 mM EDTA, 1 mM PMSF, 10% [w/v] 
sucrose) on ice. Lysozyme was added to a final concentration of 1 mg/ml. After 10 
min Triton X-100 was added to a final concentration of 0.1% [v/v]. After a further 
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10 min the samples were centrifuged in an Eppendorf centrifuge at 11 000 x g for 
1 h. The supernatants were used as crude bacterial extracts. 
Colony screening 
The length of the inserts of the deletion mutants had been characterized by 
restriction enzyme fragment length analysis. The different clones were arranged 
according to the length of the La inserts. One ~tl of a suspension of the respective 
clone was pipet-ted from a glycerol stock (17% [v/v]) directly onto a sterile 
nitrocellulose filter placed upon an ampicillin agar plate (150 ~tg/ml). The filter 
plate was incubated overnight at 37°C and further processed according to 
Sambrook et al. [19]. Immune reactions on the filter using the anti-La mAb La4B6 
were performed as described for the immunoblotting protocol using the alkaline 
phosphatase BCIPfNBT method. 
Resu l ts  
Development ofanti-La mAb La4B6 
The human recombinant La protein was expressed in E. coli and isolated from total 
bacterial extracts by two ion exchange chromatographic steps followed by immuno- 
affinity chromatography (see Materials and Methods). Although the isolated 
recombinant La protein appeared to be homogeneously purified after these steps, 
the La protein fraction used for immunization was further purified on a preparative 
denaturing SDS-polyacrylamide g l. The band corresponding to the La protein was 
excised and the La protein was eluted from the gel. This isolated La protein fraction 
was essentially free of any contaminating bacterial protein and of any degradation 
product of the La protein. After SDS-PAGE and transfer to PVDF-membrane, this 
La protein fraction gave a single band when stained with Coomassie-brilliant blue 
(Figure 1A, lane a). As expected, this protein band reacted strongly with the patient 
anti-La antibody (Figure 1A, lane b). After immunization and fusion the resulting 
hybridoma lines were screened by ELISA using the immunoaffinity purified 
recombinant La protein (see Materials and Methods). 
Only one of two obtained IgG class mAbs, termed La4B6, and none of the 9 IgM 
mAbs reacted with the La protein after SDS-PAGE and immunoblotting (Figure 
1B, lanes c to f). Interestingly, La4B6 reacted with the La protein of total extracts 
obtained from a variety of cell lines including human (Figure 1B, lane c), mouse 
(Figure 1B, lane d), rat (Figure 1B, lane e) and bovine (Figure 1B, lane f). No 
cross-reaction with another cellular protein could be detected, even when using the 
sensitive ECL  system for detection of immune complexes. 
Due to the presence of protease-sensitive PEST-regions [2], an affinity-purified 
recombinant human La protein preparation mostly contains the well-known 
N-terminal 29 kDa and the C-terminal 24 kDa domains of the La protein in 
addition to the full-length La protein. Both La fragments react with patient anti-La 
antibody (Figure 1C, lane g), although with this particular patient serum (Ma) [6] 
the reactivity to the C-terminus was less intensive (Figure 1 C, lane h which depicts 
a shorter exposure time of lane g). When the same blot was incubated with La4B6, 
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Figure 1. Characterization of the recombinant La protein and anti-La antibodies. (A) Purified 
full-length recombinant human La protein fraction stained with Coomassie-Brilliant Blue (lane a, Cb), 
and, after transfer to nitrocellulose, by the patient (Ma) anti-La antibody (lane b, P). 03) Immuno- 
blotting patterns ofmAb La4B6. The anti-La mAb La4B6 was allowed to react with the La protein on 
blots containing total extracts of human (lane c), mouse (lane d), rat (lane e) and bovine (lane f) cells. 
(C) Purified bacterially expressed recombinant La protein, containing N- and C-terminal degradation 
products in addition to the full length product, was blotted and incubated with patient anti-La antibody 
(lane g) and mAb La4B6 (lane i). lane h: A shorter exposure of lane g. 
the mAb reacted strongly with the C-terminal but not with the N-terminal fragment 
(Figure 1C, lane i). From these results we conclude that (1) the anti-La m_Ab 
La4B6 specifically reacts with the La protein and (2) the epitope locates within the 
C-terminal fragment of the La protein. 
Characterization of the anti-La mAb La4B6 by epifluorescence microscopy 
Epifluorescence microscopy revealed that the anti-La mAb gives a predominantly 
nuclear staining pattern on cells derived from human (Figure 2a) and mouse 
(Figure 2d) as well as from bovine and rat (data not shown) cell lines. In double 
labelling experiments, the staining pattern of the anti-La mAb appeared to be 
similar, but not identical, to the pattern obtained with purified patient anti-La 
antibody (compare Figure 2, lanes a and d with lanes c and f). 
Characterization of the anti-La mAb La4B6 by confocal laser scanning microscopy 
In a recent report it was shown that the use of cLSM combined with image 
processing allows the identification of nuclear substructures, which are usually not 
directly visible by classical epifluorescence microscopy [23]. Using this technique, 
which allows fading out of the homogeneous nuclear staining that is usually 
obtained after epifluorescence microscopy (Figure 2a, c, d, f, h), mAb La4B6 
produced a punctuated nuclear staining pattern (Figure 2i), while the affinity- 
purified human anti-La antibody gave a more coarse nuclear staining pattern 
(Figure 2j). To  obtain the images shown in Figures 2i and j the entire cell was cut 
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Figure 2. Images o fmAb La4B6 and patient (Ma) anti-La antibody obtained with epifluorescence and 
confocal aser scanning microscopy• Human (XPTA; a to c), and mouse (3T3; d to f) cells were stained 
with either the anti-La mAb La4B6 (a, d) or patient anti-La antibody (c, f) purified by immunoadsorp-  
tion on recombinant human La protein• The corresponding phase contrast images are shown in lanes (b) 
and (e). Bar in (c)=4 1am. The staining pattern of XPTA cells was analysed in either the non-confocal 
mode to obtain an epifluorescence pattern (h) or in the confocal mode (i, j). The images (i, j) were 
prepared by overlaying a stored stack of optical sections obtained by z-sectioning of the cell with the 
cLSM into 13 different planes at a distance of 0.5 jam. The image (k) shows a coloured overlay of(i) and 
(j). The corresponding phase contrast image is shown in (g). A similar staining pattern as shown in (j) 
for the patient anti-La antibody was also obtained when the cells were not pre-stained with the mAb but 
stained with the patient anti-La antibody only (1). 
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in z-dimension with the cLSM, resulting in 13 sections for either the FITC-stained 
patient anti-La antibody or the Cy3 stained anti-La mAb La4B6. Then an overlay 
of the stored stacks of optical sections was prepared for the series of optical sections 
of either the anti-La mAb La4B6 (Figure 2i) or the patient's anti-La antibodies 
(Figure 2j). Finally a coloured overlay of the resulting two images was made to 
more clearly show the differences between the two staining patterns (Figure 2k). 
From these results we conclude that, as might be expected, neither the anti-La mAb 
La4B6 nor the patient anti-La antibody used was able to stain all La protein 
molecules in a cell during immunofluorescence. 
Characterization of the antigenic determinant recognized by the anti-La m/tb La4B6 
In order to characterize the B cell epitope and to obtain an explanation for the 
different staining patterns of the patient anti-La antibody and the anti-La mAb 
La4B6, we decided to perform epitope mapping experiments. In a first step deletion 
mutants were prepared in which the La protein was truncated from either the N- or 
the C-terminus. In the next step the epitope region was further bordered by the use 
of synthetic peptides. 
Epitope analysis using deletion mutants of the recombinant human La protein 
The deletion mutants used for the epitope mapping experiments were prepared 
from the human La cDNA clones La l9  and La23 (see Materials and Methods). 
Both clones contain the complete coding region of the La protein. However, in the 
case of La 19 the La insert was inverted uring cloning in the pBluescript vector. In 
consequence, deletion of these two clones from the same site resulted in deletion 
mutants expressing the La proteins being truncated from either the N-terminus 
(derived from La23) or the C-terminus (derived from Lalg).  
In total, 85 deletion mutants were selected. Clones 1 to 38 were derived from 
La23 and clones 39 to 85 from Lal9.  The clones were analysed by colony screening 
(Figure 3A). On the filter the clones were arranged according to the length of their 
inserts. Neighbouring clones differed about 30 to 100 nts in length. As explained in 
Materials and Methods, clones 23-25 were not or less efficiently expressed and 
therefore not very useful. Clone 22 contained the smallest La insert being still 
reactive with the anti-La mAb after expression into a l~l-terminally truncated 
La protein. It starts with the aa V (305). The longest non-reactive clone expressing 
La protein truncated from the N-terminus is clone 26, which starts with aa A (384). 
In consequence, the N-terminal deletion mutants locate the epitope between aa 
305 and aa'384. 
In the case of clones expressing the La protein truncated from the C-terminus the 
most interesting clones were clone 54 (ending at aa G (342)) whicl~ was still 
reactiCe, and clone 55 (ending at aa S (331)) which was th~ longest n0n-reactive 
clone. As summarized in Figure 3B, the colony screening ekperiments indicated 
that the epitope was located between aa 331 and 34~. 
The results of the colony screening experiments were confirmed by analysis of the 
bacterial extracts by-immtmoblotting '.(Figure 4A-C). In this type of experiment 
extracts obtained from bacteria expressing either the full length clone Lal  9 (Figure 
t 
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Figure 3. La4B6 epitope mapping by deletion mutant analysis. (A) Bacteria expressing deletion 
mutants of the La protein truncated from either the N-terminus (1 to 38) or the C-terminus (39 to 85) 
were analysed for reactivity with the anti-La mAb La4B6. Clone 54 encodes aLa protein mutant ending 
at aa G (342), while clone 55 ends with the aa S (331). The clones 22 and 26 started with e aa V (305) 
or aa A (384), respectively. Clones 23 to 25 were not able to express La protein derivatives ( ee Materials 
and Methods). The non-reactive clones (23 to 38 and 55 to 85) gave similar background staining 
intensities as the bacteria containing the pBluescript vector only (arrow). (B) Summary of the results of 
the colony screening experiment. The N-terminal deletion mutants 22 and 26 locate the epitope 
between aa 305 and 384; the C-terminal deletion mutants 54 and 55 locate it between aa 331 and 342. 
The reactivity of the various clones is listed on the right. 
4A-C ,  lanes  b and  c) or  the  de le t ion  mutants  c lone  55 (F igure  4A-C ,  lanes  e and  
f)  or  c lone  54 (F igure  4A-C ,  lanes  g and  h)  were  ana lysed  by  immunob lo t t ing .  
Tota l  ext racts  o f  bacter ia  t rans formed w i th  the  pB luescr ip t  vector  lack ing  an  inser t  
were  used  as a negat ive  cont ro l  (F igure  4A-C ,  lanes  a and  d).  In  the  f irst par t  o f  the  
exper iment  the  t rans fer red  prote ins  were  probed w i th  the  ant i - La  mAb La4B6.  The  
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Figure 4. Analysis of reactivity of patient antibody and mAb La4B6 with deletion mutants by 
immunoblotting. (A) Extracts from bacteria not expressing any La product (lanes a, d) or expressing 
either full length La (lanes b, c) or deletion mutants 55 (lanes e, f) or 54 (lanes g, h) were allowed to 
react with patient anti-La antibody in order to ensure that comparable amounts of La product were 
present on the blots. (B) The same blots as in (A) were incubated With mAb La4B6. (C) Overexposure 
of the blots shown in (B). 
immune complexes formed were visual ized using the ECL  system (Figure 4B and 
C). After detect ion,  the immune complexes were eluted from the blot  and the same 
blot was re - incubated with the pat ient  ant i -La ant ibody.  As is evident f rom the blot 
incubated with the pat ient  ant i -La nt ibody (F igure 4A), the bacter ial  extract of  
every La clone conta ined the respective immunoreact ive  La protein.  In contrast  o 
the pat tern  obta ined with the pat ient  ant i -La ant ibody but  in agreement  with the 
colony screening exper iments,  the ant i -La mAb La4B6 did react with delet ion 
mutant  54 (F igure 4B and C, lanes g and h) but  not  with delet ion mutant  55 
(F igure 4B and C, lanes e and f). 
As can be seen in F igure 4A, the La prote in  der ived f rom clone 54, p resumed to 
be 11 aa longer than the La prote in derived from clone 55, migrates faster dur ing 
SDS-PAGE.  Th is  is explained as follows. Dur ing  preparat ion  of  the delet ion 
mutants ,  clones 54 and 55 lost the C- termina l  stop codon o f  the La cDNA.  As a 
consequence,  terminat ion of  translat ion of  the respective La clone takes place at the 
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first in-frame stopcodon encoded by the vector sequence, which differs in position 
between both clones, leading to an additional C-terminal peptide of 11 aa in case of 
clone 54 and of 47 aa in case of clone 55. Thus the La protein derived from clone 
55 is 25 aa longer than the La product derived from clone 54 explaining the faster 
migration of the latter. 
Finally this experiment also shows that mAb La4B6 does not cross-react with any 
bacterial epitope, as the pBluescript control is absolutely negative (Figure 4B and 
C, lanes a and d). In summary, from the colony screening and the immunoblotting 
analyses it can be concluded that at least part of the autoepitope is located in the 
region between the ends of clones 55 and 54, i.e. between nts 992-1024 of the 
human La cDNA sequence, which codes for the aa sequence 332KGRRFKG- 
KGKG 342. 
Analysis of the epitope using synthetic peptides 
In order to determine whether the identified region represents either the complete 
epitope or a N- or C-terminal part of it, synthetic peptides were made based on the 
aa sequence 331SKGRRFKGKGKGN343 (peptide 1, Figure 5) which was short- 
ened from the N-terminus. The reactivity of the resulting peptides was determined 
by ELISA and the results are summarized in Figure 5. Peptide 2 (lane 2) lacking the 
N-terminal aa S (331) was already less reactive than the complete sequence. 
Further shortening resulted in a progressive loss of reactivity (Figure 5, peptides 3 
to 5). After removing the first three aa SKG (peptide 4, lane 4), the remaining 
peptide sequence 334RRFKGKGKGN343 showed a reactivity of less than 15% as 
compared with the complete peptide 1. In consequence, the aa sequence SKG 
appeared to be an essential part of the epitope. To rule out that the observed 
decrease in reactivity was due to a gradual oss of binding affinity of the respective 
peptide to the ELISA plate, additional peptides with an identical ength of 11 aa 
were made. Each of these dodecamers contained (1) a part of the epitope including 
the aa, either SKG 333 (peptide 9, Figure 5), or SKGRR 335 (peptide 8) or 
SKGRRFKG 338 (peptide 6) and (2) the respective upstream flanking sequence. 
Only peptide 6 (32sK~rKSKGRRFKG 33s) was well recognized by mAb La4B6. 
Replacing the three N-terminal aa KWK of this peptide with the unrelated 
sequence IEV, as in peptide 7, did not affect the reactivity. From these results we 
concluded that the epitope probably starts at position 331 (S). 
As shown in Figure 5, peptide 6 was somewhat less reactive than peptide 1. This 
could be explained by the different length of the peptides (13 aa (peptide 1) vs 11 
aa (peptide 6)) or by the five additional C-terminal aa KGKGN in peptide 1 which 
might be involved in formation of the complete pitope. To  differentiate between 
these two possibilities the two peptides were covalently linked to BSA at the same 
molar ratio. When these conjugates were analysed in comparison to BSA the same 
difference in activity as was found earlier for the  unconjugated peptides was 
obtained (data not shown). Therefore, the sequence 339KGKGN343 downstream of 
the sequence 33XSKGRRFKG338 partially contributes to the complete pitope. In 
parallel~the reactivity of recombinant human La protein was measured. BSA 
conjugated with peptide 1 had 37% of the reactivity of the recombinant humari La 
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Figure 5. La4B6 epitope mapping using synthetic peptides, each comprising part of the aa sequence 
of the human epitope region identified by colony screening, 331(S)KGRRFKGKGKG(N)343, were 
made. The reactivity of the anti-La mAb to these peptides was measured by ELISA (see Materials and 
Methods). Background activity levels were measured using po]ylysine, BSA and a non-related control 
peptide VYVVPWEKK (lanes 10). lane 1: peptide 1 (aa 331-343). The reactivity of this peptide was set 
at 100%; lane 2: peptide 2 (aa 332-343); lane 3: peptide 3 (aa 333-343); lane 4: peptide 4 (aa 334-343); 
lane 5: peptide 5 (aa 335-343); lane 6: peptide 6 (aa 328-338); lane 7: peptide 7, the aa 32SKWKa3° 
in peptide 6 were changed into JEV; lane 8: peptide 8 (aa 325-335); lane 9: peptide 9 (as 323-333); 
lane 11 : peptide 11, consisting of the two epitope parts SKG and RFKG, interrupted by part of the 
mouse-specific nsert. 
protein, suggesting that addit ional sequences in the La protein might  be involved in 
correct epitope formation. 
It was noted that the epitope does not  exist as a cont inuous aa sequence in the rat 
and mouse  La proteins. In the mouse  La protein (the aa posit ions for the mouse  La 
protein are given in italics) it is split by the species-specif ic insert Z33GHAG- 
GRFKGS~AA 34s into two parts consist ing o f  the N- termina l  aa 33°SKGZ32 
and the C-terminal  aa 349RRFKGKGKGN z5s. This  C-terminal  part RRFKGKG-  
KGN cannot account  for the b ind ing o f  La4B6 to mouse  or rat La proteins 
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Figure 6. Effect ofATP on binding of the anti-La rnAb La4B6 torecombinant human La protein. 
Increasing amounts of recombinant human La protein (A to D, lanes a: 0.2 lag, lanes b: 0.4 tag, lanes c: 
0.8 ~tg, lanes d: 1.6 ~tg) were blotted and incubated with the anti-La mAb La4B6 in the presence of 
150mM of ATP (A) or in the absence of ATP (B). The same blots, after removing La4B6 
immuno-complexes by washing with 0.2 M glycine/HCl (pH 2.3; 500 mM NaC1), were re-incubated 
with patient anti-La antibody again in the presence and absence of ATP (C and D). 
observed in immunoblott ing and immunofluorescence (Figures 1 and 2) since this 
sequence has only a very low affinity towards the monoclonal  antibody (Figure 5, 
lane 4). Therefore, another synthetic peptide was made containing at the 
N-terminal  side the aa sequence SKG followed by part of  the mouse specific insert 
S3SGHAGGRFKGS41, which also contains the partial repeat (RFKG)  of  the 
C-terminal epitope sequence. Interestingly, this peptide 11 showed about 80% of 
the reactivity exhibited by the corresponding human linear sequence (compare 
lanes 11 and 1). Consequently (1) the C-terminal part 339KGKGN343 of the 
human epitope 331SKGRRFKGKGKGN343 is not absolutely required for binding 
of  the anti=La mAb La4B6 and (2) the two parts 331SKG333 and 334RRFKG 338 of 
the human epitope do not necessarily have to exist as a linear peptide. As the second 
half of  the mouse epitope S49RRFKG s53 is partially (S3SRFKG s41) repeated in the 
rat and mouse insert it is difficult to decide whether the first or the second or both 
RFKG sequences are involved in autoepitope formation in the rat and mouse La 
proteins. In conclusion, our data suggest that the autoepitope in the mouse La 
protein which is recognized by the mouse mAb La4B6 is a conformational 
epitope formed by the aa sequence 3s°SKGGHAGGRFKGSHVF'FAA 
RRFKGKGKGN sSs. 
Blocking of the epitope by A TP 
Interestingly, the identified epitope region coincides with the predicted ATP-  
binding site of  the La protein. Therefore we analysed the effects of  ATP  on the 
reactivity of  anti-La mAb La4B6 with recombinant human La protein. For  that 
purpose increasing amounts of  recombinant human La protein (Figure 6) were 
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blotted and incubated with the mAb La4B6 in the presence of 150 mM ATP 
(Figure 6A) or in the absence of ATP (Figure 6B). The results clearly indicate that 
ATP is able to abolish the binding of the mAb La4B6 to the recombinant human La 
protein. The same blots, after removal of the La4B6 immuno-complexes, were 
re-incubated with patient anti-La antibody to show that ATP did not detectably 
influence the recognition of La by patient antibodies. Also, lower concentrations of
ATP (10-100 nM) were able to interfere with the binding of mAb La4B6 to La 
(data not shown). From these experiments we conclude that ATP is able to 
compete with mAb La4B6 for binding to La, probably by binding to the epitope 
region recognized by this monoclonal antibody. 
Discuss ion  
Sera of patients with systemic autoimmune diseases frequently contain autoanti- 
bodies to the nuclear autoantigen La/SS-B. Mouse monoclonal antibodies directed 
to the La protein have been described by several groups [6, 12, 25-27] but in most 
cases these anti-La mAbs either do not cross-react with the mouse La protein [25, 
27] or behave differently with respect o their staining pattern and RNA coprecipi- 
tation properties if compared to patient anti-La antibodies [6, 12]. Recently, La 
cDNA sequences encoding the rat and mouse La protein became available and 
sequence comparison revealed that species-specific inserts appeared to be present in 
the human, bovine, rat and mouse La sequences [9, 11]. To test whether these 
regions could have autoantigenic properties, mice were immunized with a recom- 
binant human La protein preparation and the resulting hybridomas were analysed 
for cross-reactivity with the mouse La protein. The anti-La mAb La4B6 was found 
to react with the human, bovine, rat and mouse La protein both in immuno- 
fluorescence and immunoblotting. In epifluorescence microscopical studies the 
anti-La mAb La4B6 gave a comparable staining pattern to the patient anti-La 
antibody. However, if the immuno-stainings were analysed with the cLSM tech- 
nique, differences between the staining patterns of the patient anti-La antibody and 
the anti-La mAb La4B6 became evident. The discrepancies between the staining 
patterns were not due to competition of the antibodies during the staining process 
because they could be observed in double as well as in single immunofluorescence 
studies (Figure 2). 
To  explain these discrepancies in staining patterns and to obtain some idea of 
the mechanism leading to activation of a mouse autoreactive B cell, we character- 
ized the human epitope region and compared it with the sequence of the 
corresponding mouse La autoepitope. All epitope mapping experiments, includ- 
ing N- and C-terminal deletion mutants (Figures 1C, 3, 4), and the use of 
synthetic peptides (Figure 5) locate the epitope in the C-terminal part of the La 
protein. In contrast, the patient anti-La antibody used in this study preferentially 
reacted with the N-terminal part of the La protein (Figure 1C). A possible 
explanation for the different staining pattern of the mAb La4B6, as compared to 
the patient antibody, is that the La4B6 epitope on the La protein might not 
always be accessible. 
The epitope sequence could be analysed in detail by the use of synthetic peptides 
(Figure 5). Taken together, five of the peptides used to characterize the epitope 
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region (peptides 3, 6 to 9) had the same length of 11 aa. The number of charged aa 
within these peptides ranged from 3 (peptides 10, 11) to 6 (peptides 1, 2). 
However, these differences in the number of charged aa seemed not to be relevant. 
For example, the peptides 6 and 7 showed the same high reactivity although they 
contain 6 and 4 positively charged aa, respectively, while peptides 8 and 9 
containing 5 and 3 positively charged aa, respectively, gave comparable low 
reactivities. 
Recently Topfer et al. [9] identified an ATP-binding motif in the La protein 
which appeared to be part of the epitope region identified for the anti-La mAb 
La4B6. In agreement with this suggestion it was found that ATP effectively 
competes for the binding of mAb La4B6 to the La protein (Figure 6). 
Interestingly, the identified human epitope sequence is split in the mouse and rat 
La protein into two parts by one of the recently identified species pecific inserts. As 
synthetic peptides containing either the N-terminal part of the human epitope 
(SKG) or the C-terminal part (RRFKGKGKGN)  did not react with the anti-La 
mAb La4B6, while a synthetic peptide containing the two epitope parts separated 
by the mouse specific insert was well recognized by La4B6, we hypothesize that the 
three-dimensional organization of the human and mouse La4B6 epitope must be 
similar. However, in the case of the human La protein the epitope region is formed 
by a continuous aa sequence, while in the mouse La protein the insert and the two 
parts of the epitope are probably folded in such a way that a similar arrangement of
amino acids crucial for the epitope is obtained. This conformational rrangement 
might be evolutionarily conserved ue to the fact that it represents a fimctional 
entity of the La protein (ATP binding site). The difference in folding of this region 
between the human, mouse and rat La protein might also explain the increased 
sensitivity to denaturation of the mouse and rat La epitope which was observed in 
some experiments (data not shown). 
Epitope mapping studies have also been performed in previous tudies (reviewed 
in 28). In most cases immunization of mice with human or bovine La protein 
resulted in species restricted reactivities of the anti-La mAbs [25, 27]. Two groups 
immunized mice with bovine La protein and obtained either bovine specific anti-La 
mAbs [27] or anti-La mAbs cross-reacting with human and bovine but not with 
mouse La protein [25]. The epitopes recognized by these antibodies are therefore 
probably directed to less conserved regions and most probably not to functional 
entities of the La protein [29]. 
Human autoantibody populations frequently contain antibodies directed to the 
same epitopic region shown to be targeted by La4B6. Rauh and coworkers 
described that one of at least three human B-cell epitopes locates within a fragment 
spanning aa 292-345 [30]. Similarly, Sturgess et al. [31] reported an anti-La 
reactivity directed to a fragment between aa 305 and 408. Also Chambers et al. [32] 
and St Clair et al. [33] identified an antigenic region between the aa 242 to 408. 
Finally, Kohsaka and coworkers [34] performed fine epitope mapping and identi- 
fied several autoantigenic La protein regions. Some of these regions were recog- 
nized by many sera, others by only a few. One of the commonly recognized regions 
included the aa 283-338. Interestingly, the epitope (aa 331-343) recognized by the 
anti-La mAb La4B6 is contained in all autoantigenic regions identified by the 
studies mentioned above. Moreover, it locates within a conserved functional region 
HRA La/SS-B activates mur ine autoreactive B cell 841 
of the La protein. Finally, the mouse mAb La4B6 cross-reacts from human to 
mouse and thus represents an experimentally induced autoantibody. 
Acknowledgements 
This investigation was supported by a grant from the German Research Society 
(Deutsche Forschungsgemeinschaft,  DFG (Ba 1145/1-2)). M. Bachmann is a 
recipient of a Hermann-and-Li l ly-Schi l l ing professorship granted by the 'Stifterver- 
band ffir die Deutsche Wissenschaft' .  I. Semsei is a recipient of  a fellowship 
donated by the Alexander von Humboldt-St i f tung.  M. Schwemmle is a recipient of  
an Isaac L indenmann scholarship. The  research of  G. J. M. Pruijn has been made 
possible by a fellowship of  the Royal Netherlands Academy of Arts and Sciences. 
The  work of  W. J. van Venrooij was supported in part by the Netherlands 
Foundat ion for Chemical Research (SON) with financial aid from the Netherlands 
Organization for Scientific Research (NWO).  
References 
1. Tan, E. M. 1989. Antinuclear antibodies: Diagnostic markers for autoimmune diseases 
and probes for cell biology. Adv. Immunol. 44:93-151 
2. Van Venrooij, W. J., R. L. Slobbe, and G. J. M. Pruijn. 1993. Structure and function of 
La and Ro RNPs. Mol. Biol. Rep. 84:113-121 
3. Gottlieb, E. and J. A. Steitz. 1989. The RNA binding protein La influences both the 
accuracy and the efficiency of RNA polymerase III transcription in vivo. EMBO J. 8: 
841-850 
4. Gottlieb, E. and J. A. Steitz. 1989. Function of the mammalian La protein: evidence for 
its activity in transcription termination by RNA polymerase III. EMBOff.  8:851-861 
5. Hendrick, J. P., S. Wolin, J. Rinke, M. Lemer, and J. A. Steitz. 1981. Ro small 
cytoplasmic ribonucleoproteins are a subclass of La ribonucleoproteins: Further char- 
acterization of the Ro and La small ribonucleoproteins from uninfected mammalian 
cells. Mol. Cell. Biol. 12:1138- I  149 
6. Bachmann, M., K. Pfeifer, H. C. Schrrder, and W. E. G. Mtiller. 1990. Characteriza- 
tion of the autoantigen La as a nucleic acid dependent ATPase/dATPase with melting 
properties. Cell 60" 85-93 
7. Meerovitch, K., Y. V. Svitkin, H. S. Lee, F. Leibkowicz, D. Kenan, E. K. L. Chan, V. I. 
Agol, J. D. Keene, and N. J. Sonenberg. 1993. La autoantigen enhances and corrects 
aberrant translation of poliovirus RNA in reticulocyte lysate. J. Virol. 67:3798-3807 
8. Xiao, Q., T. V. Sharp, I. W. Jeffrey, M. C. James, G. J. M. Pruijn, W. J. van Venrooij, 
and M. J. Clemens. 1994. The La antigen inhibits the activation of the interferon- 
inducible kinase PKR by sequestering and unwinding double-stranded DNA. Nucleic 
Acids Res. 22:2512-2518 
9. Topfer, F. T., T. Gordon, and J. McCluskey. 1993. Characterization of the mouse 
autoantigen La (SS-B): Identification of conserved RNA binding motifs, a putative 
ATP binding site and reactivity of recombinant protein with poly(U) and human 
autoantibodies, ft. Immunol. 10:3091-3097 
10. Pause, A. and N. J. Sonenberg. 1992. Mutational analysis of a DEAD box RNA 
helicase: the mammalian translation initiation factor eIF-4A. EMBO ft. 11:2643-2654 
1 I. Semsei, I., H. Trrster, H. Bartsch, M. Schwemmle, G. Igloi, and M. Bachxnarm. 1993. 
Cloning of the autoantigen La/SS-B from a rat cDNA library: Detection of species- 
specific variations. Gene 126:265-268 
12. Bachmann, M., W. J. Mayer, H. C. Schr6der, K. Pfeffer, K.-H. Meyer zum Bfischenfelde, 
and W. E. G. Miiller. 1986. Association of La and Ro antigens with intracellular 
structures in HEp-2 carcinoma cells. Proc. Natl. Acad. Sci. USA 83:7770-7774 
842 H. Tr6ster et al. 
13. Bachmann, M., K. Pfeifer, H. C. Schr6der, and W. E. G. M/Jller. 1987. The 
nucleocytoplasmic shuttling of the La antigen in CV-1 cells. Mol. Biol. Rep. 12:239-240 
14. Bachmann, M., Th. Zaubitzer, and W. E. G. Mfiller. 1992. The autoantigen La/SS-B: 
Detection and uptake by mitotic cells. Exp. Cell Res. 201:387-398 
15. Bachmann, M., H. Althoff, C. Selenka, D. Falke, and W. E. G. MUller. 1992. 
Translocation of the nuclear autoantigen La/SS-B to the cell surface of herpes simplex 
type 1 infected cells. Autoimmunity 12:37-45 
16. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head 
of bacteriophage T4. Nature 227:680-685 
17. Matsudaira, P. 1987. Sequence from picomole quantities of proteins electroblotted onto 
polyvinylidene difluoride membranes. J. Biol. Chem. 262:10035-10038 
18. Holmes, D. S. and B. Quigley. 1981. A rapid boiling method for the preparation of 
bacterial plasmids. Anal. Biochem. 114:193-197 
19. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular Cloning: A Laboratory 
Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. 
20. Henikoff, S. 1987. Unidirectional digestion with exonuclease III in DNA sequence 
analysis. Methods in Enzymology 115:156-165 
21. Slobbe, R. L., W. Pluk, W. J. van Venrooij, and G. J. M. Pruijn. 1992. Ro ribonucleo- 
protein assembly in vitro. J. Mol. Biol. 227:361-372 
22. Studier, F. W. and B. A. Moffat. 1986. Use of bacterial phage T7 RNA polymerase to 
direct selective high-level expression of cloned genes. J. Mol. Biol. 189:113-119 
23. Bachmarm, M., S. Chang, H. Slor, J. Kukulies, and W. E. G. M/.iller. 1990. Shuttling of 
the autoantigen La between nucleus and cell surface after UV irradiation of human 
keratinocytes. Exp. Cell Res. 191:171-181 
24. Chan, E. K. L., A.-M. Francoeur, and E. M. Tan. 1986. Epitopes, structural domains, 
and asymmetry of amino acid residues in SS-B/La nuclear protein. J. Immunol. 136: 
3744-3749 
25. Chan, E. K. L. and E. M. Tan. 1987. Human autoantibody-reactive epitopes of 
SS-B/La are highly conserved in comparison with epitopes recognized by murine 
monoclonal antibodies. J Exp. Med. 166:1627-1640 
26. Smith, P. R., D. G. Williams, P. J. W. Venables, and R. N. Maini. 1985. Monoclonal 
antibodies to the Sj6gren's yndrome associated antigen SS-B (Ida). J. immunol. Methods 
77" 63-69 
27. Harley, J. B., M. O. Rosario, H. Yamagata, O. F. Fox, and E. Koren. 1985. 
Immunologic and structural studies of the Lupus/Sj6gren's syndrome autoantigen, 
La/SS-B, with a monoclonal antibody..7. Clin. Invest. 76:801-806 
28. Pruijn, G. J. M. 1994. The La(SS-B) antigen. In W. J. van Venrooij and R. N. Maini, 
eds. Manual of Biological Markers of Disease. Kluwer Academic Publishers, Dordrecht. 
I ]4.2:1-14 
29. Chart, E. K. L. and E. M. Tan. 1989. Epitopic targets for autoantibodies in systemic 
lupus erythematosus and Sj6gren's yndrome. Gun'. Opin. Rheumatol. 1:376-381 
30. Rauh, A. J. G., H. Hornig, and R. Likhrmann. 1988. At least three distinct B cell 
epitopes reside in the C-terminal half of La protein, as determined by a recombinant 
DNA approach. Fur. J. Immunol. 18:2049-2057 
31. Sturgess, A. D., M. G. Peterson, L. J. McNeilage, S. Wit~ingham, and R. L. Coppel. 
1988. Characteristics and epitope mapping of a cloned human autoantigen La. 
J. Immunol. 140:3212-3218 
32. Chambers, ]'. C., D. Kenan, B. J. Martin, and J. D. Keene. 1988. Genomic structure and 
amino acid sequence domains of the human La autoantigen. J. Biol. Chem. 263: 
18043-18051 
33. St Clair, E. W., D. S. Pisetsky, C. F. Reich, and J. D. Keene. 1988. Analysis of 
autoantibody binding to different regions of~the human La antigen expressed in' 
recombinant fusion proteins. J. Immunol. 141:4173-4180 
34. Kohsaka, H., K. Yamamoto, H. Fujii, H. Miura, and N. Miyasaka. 1990. Fine epitope 
mapping of the human SS-B/La protein. J. Clin. Invest. 6:2233--2244 
